Article Text

Download PDFPDF
Impact of antifibrotic therapy on lung cancer development in idiopathic pulmonary fibrosis
  1. Hyogo Naoi1,
  2. Yuzo Suzuki1,
  3. Kazutaka Mori2,
  4. Yuya Aono1,
  5. Masato Kono3,
  6. Hirotsugu Hasegawa3,
  7. Koshi Yokomura3,
  8. Yusuke Inoue1,
  9. Hironao Hozumi1,
  10. Masato Karayama1,
  11. Kazuki Furuhashi1,
  12. Noriyuki Enomoto1,
  13. Tomoyuki Fujisawa1,
  14. Yutaro Nakamura1,
  15. Naoki Inui1,
  16. Hidenori Nakamura3,
  17. Takafumi Suda1
  1. 1Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
  2. 2Department of Respiratory Medicine, Shizuoka City Shimizu Hospital, Shizuoka, Japan
  3. 3Department of Respiratory Medicine, Seirei Mikatahara Hospital, Hamamatsu, Japan
  1. Correspondence to Dr Yuzo Suzuki, Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan; yuzosuzu{at}hama-med.ac.jp

Abstract

Patients with idiopathic pulmonary fibrosis (IPF) are at a high risk of lung cancer (LC). Antifibrotic therapy slows disease progression and possibly prolongs survival. However, whether antifibrotic therapy affects LC development in patients with IPF remains unknown. This multicentre retrospective study evaluated 345 patients with IPF. The incidence and prevalence of LC were significantly lower in patients with IPF receiving antifibrotic therapy than those not receiving. Subsequently, LC-related mortality was significantly lower in patients with IPF receiving antifibrotic therapy. These results suggest that antifibrotic therapy was possibly associated with a reduced risk of LC development in patients with IPF, which may be partly associated with its survival benefit.

  • Idiopathic pulmonary fibrosis
  • Lung Cancer

Statistics from Altmetric.com

Footnotes

  • Contributors HNao and YS: conception and design, data collection, data analysis and interpretation, manuscript writing and final approval of the manuscript. KM: statistical analysis, data collection and data analysis. YA, MK, HHa and KY: conception and design, data collection and data analysis. YI, HHo, MK, KF, NE, TF, YN, NI and HNak: data collection, data analysis and supervision. TS: conception and design, manuscript writing and administrative support.

  • Funding This work was supported by a grant-in-aid for scientific research (19K17632 to YS) from the Japan Society for the Promotion of Science.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.